Infants up to 6 weeks old with genetically diagnosed presymptomatic spinal muscular atrophy (SMA) treated with oral risdiplam ...

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $165.9, a high estimate of $219.00, and a low estimate of $115.00. This current ...

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...

A coffee variety called liberica, which is gaining popularity for the distinctive flavour of its beans, is actually three ...

Piper Sandler raised the firm’s price target on Biogen (BIIB) to $118 from $115 and keeps a Neutral rating on the shares. The ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

Chinese authorities did not renew a conditional approval of Green Valley Pharmaceuticals’ controversial Alzheimer’s disease ...

Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...